Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 245–252 | Cite as


Future prospects
  • B. C. M. J. Takx-Köhlen
Drugs in the Pipeline


The future role of the immunomodulators in medical practice is yet to be defined. The key question is whether these new substances will bring remarkable progress in transplantation or in the treatment of such conditions as cancer, AIDS, and autoimmune diseases, or whether they will be of only minor adjunctive importance. As background to the discussion of immunomodulating agents, the immune system is explained, with emphasis on the roles of T and B lymphocytes, macrophages, phagocytes, human leukocyte antigen and the complement system. Special attention is given to the cytokines, particularly the lymphokines. The immunomodulators can be divided into three main groups: immunosuppressive agents, such as FK 506 and rapamycin; immunostimulating agents, of which BCG vaccine is most important; and the remaining immunomodulators, which include the biological response modifiers.The last group, which encompasses the colony-stimulating factors (GM-CSF, G-CSF, and M-CSF), the interleukins, the interferons, and the tumour necrosis factors, is described in detail. Innovative research and medical applications of these cytokines, including indications, contraindications, and adverse reactions, are discussed. The role of monoclonal antibodies against endotoxins is also described.


Cytokines Haematopoietic growth factors Immunomodulators Interferons Interleukins Lymphocytes Lymphokines Monoclonal antibodies Tumor necrosis factors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Oliver JF. Opportunistic infections in immunocompromised patients. Assessment skills for pharmacists 1988. Palo Alto: Syntex Laboratories Inc., 1988.Google Scholar
  2. 2.
    Tami AJ, Parr MD, Thompson JS. The immune system. Am J Hosp Pharm 1986;43:2483–93.PubMedGoogle Scholar
  3. 3.
    Melief CJM, Kast WM. Immunogenicity of tumors and viral oncogene directed immunotherapy. In: Van der Erb AJ, ed. Immunotherapy of cancer. Leiden: Boerhaave Committee for Postgraduate Medical Education, Leiden University, 1991.Google Scholar
  4. 4.
    Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667–74.PubMedGoogle Scholar
  5. 5.
    Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987;317:940–5.PubMedGoogle Scholar
  6. 6.
    Kintzel PE, Calis KM. Recombinant interleukin-2. A biological response modifier. Clin Pharm 1991;10: 110–28.PubMedGoogle Scholar
  7. 7.
    Van Dijk H. Verbindingen met een immuunmodulerend effect. Pharm Weekbl 1984;119:831–5.Google Scholar
  8. 8.
    Van Dijk H. Immuunmodulerende eigenschappen van farmaca. Pharm Weekbl 1982;117:1144–7.Google Scholar
  9. 9.
    Schellekens PThA, Ten Berge RJM. The effects of immunosuppressive drugs on human immunocompetence. Pharm Weekbl [Sci] 1984;6:32–8.Google Scholar
  10. 10.
    Macleod AM, Thomson AW. FK 506: an immunosuppressant for the 1990s. Lancet 1991;337:25–7.PubMedGoogle Scholar
  11. 11.
    Calne RY, Lim S, Samaan A, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227.Google Scholar
  12. 12.
    Anonymous. Topical BCG for recurrent superficial bladder cancer. Lancet 1991;337:821–2.Google Scholar
  13. 13.
    Mutch RS, Hutson PR. Levamisole in the adjuvant treatment of colon cancer. Clin Pharm 1991;10:95–109.PubMedGoogle Scholar
  14. 14.
    Groopman JE, Molina JM, Scadden DT. Haematopoietic growth factors. N Engl J Med 1989;321:1449–59.PubMedGoogle Scholar
  15. 15.
    Hansen HH, Kristjansen PEGA, Andersen M. Small cell lung cancer. The role of haemotopoietic growth factors. Macclesfield: Gardiner-Caldwell Communications, 1990:21–7.Google Scholar
  16. 16.
    O'Garra A. Interleukins and the immune system. Lancet 1989;-1:943–6.PubMedGoogle Scholar
  17. 17.
    Metcalf D. Haemopoietic growth factors 1. Lancet 1989;1:825–7.PubMedGoogle Scholar
  18. 18.
    Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunology Lett 1988;19:183–92.Google Scholar
  19. 19.
    Sakai A, Kawanon Kuramoto A. Interleukin-6 produced by renal-cell, carcinoma cells and progression of multiple myeloma. N Engl J Med 1991;324:1893–4.PubMedGoogle Scholar
  20. 20.
    Metcalf D. Haemopoietic growth factors 2; clinical applications. Lancet 1989;1:885–7.PubMedGoogle Scholar
  21. 21.
    Hoekman K, Wagstaff J, Ossenkoppele GJ, Pinedo HM. De toepassing van hematopoëtische groeifactoren in de oncologie. Ned Tijdschr Geneeskd 1991;135:409–14.PubMedGoogle Scholar
  22. 22.
    Hoekman K, Wagstaff J, Boven E, Van Groeningen CJ. Vermorken JB, Pinedo HM. Hematopoëtische groeifactor GM-CSF bij Chemotherapie wegens voortgeschreden mammacarcinoom. Ned Tijdschr Geneeskd 1991;135:415–9.PubMedGoogle Scholar
  23. 23.
    Biemsa B, Willemse PHB, Vellenga E, Limburg PC, Aalders JG, De Vries EGE. Hematopoëtische groeifactor GM-CSF bij Chemotherapie wegens ovariumcarcinoom. Ned Tijdschr Geneeskd 1991;135:420–4.PubMedGoogle Scholar
  24. 24.
    Hogan KR. Granulocyte-macrophage colonystimulating factor in neutropenia. DICP Ann Pharmacother 1991;-25:32–5.Google Scholar
  25. 25.
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773–8.PubMedGoogle Scholar
  26. 26.
    McManus Balmer C. Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2. DICP Ann Pharmacother 1991;25:490–8.Google Scholar
  27. 27.
    Crawford J, Ozer H, Stoller R, et al. Reduction by granylocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer. N Engl J Med 1991;325:164–70.PubMedGoogle Scholar
  28. 28.
    Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871–7.PubMedGoogle Scholar
  29. 29.
    Wiltink EHH. Bloedgroeifactoren. Granulocyte colonystimulating factor en granulocyte-macrophage colonystimulating factor. Pharm Weekbl 1991;126(31):746–53.Google Scholar
  30. 30.
    Horohov DW, Siegel JP. Lymphokines. Progress and promise. Drugs 1987;33:289–95.PubMedGoogle Scholar
  31. 31.
    Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989;25Suppl 3:S21–8.Google Scholar
  32. 32.
    Stoter G, Shiloni E, Aamdal S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989;25 Suppl 3:S41–3.Google Scholar
  33. 33.
    West WH. Clinical application of continuous infusion of recombinant interleukin-2. Eur J Cancer Clin Oncol 1989;3 Suppl 3:S11–5.Google Scholar
  34. 34.
    Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988;15 Suppl 6:10–26.Google Scholar
  35. 35.
    Rosenberg SA. Clinical immunotherapy studies in the surgery branch of the US National Cancer Institute: brief review. Cancer Treatm Rev 1989;16 Suppl A:115–21.Google Scholar
  36. 36.
    Heremans H, Bilian A. The potential role of interferons and interferon antagonists in inflammatory disease. Drugs 1989;6:957–72.Google Scholar
  37. 37.
    McManus Balmer C. Clinical use of biologic response modifiers in cancer treatment. Part I. The interferons. DICP Ann Pharmacother 1990;24:-761–7.Google Scholar
  38. 38.
    Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295–301.PubMedGoogle Scholar
  39. 39.
    Herzenberg H. Interferon alfa-2b for chronic hepatitis B. N Engl J Med 1991;324:493–4.PubMedGoogle Scholar
  40. 40.
    International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509–16.Google Scholar
  41. 41.
    Exley AR, Cohen J, Buurman W. Monoclonal antibody to TNF in severe septic shock. Lancet 1990;335:1275–7.Google Scholar
  42. 42.
    Speelman P, Van Deventer SJH. Behandeling van patiënten met een door Gram-negative bacteriën veroorzaakte sepsis met monoklonale anti-endotoxine-antistoffen. Ned Tijdschr Geneesk 1991;135:877–78.Google Scholar
  43. 43.
    Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429–36.PubMedGoogle Scholar
  44. 44.
    Wolff SM. Monoclonal antibodies and the treatment of Gram-negative-bacteremia and shock. N Engl J Med 1991;324:486–8.PubMedGoogle Scholar
  45. 45.
    Ziegler EJ, Fisher CJ, Sprung CL, Smith CR, Sadoff JC, Dellinger RP. The HA-1A monoclonal antibody for Gram-negative sepsis. N Engl Med 1991;32–5:282–3.Google Scholar
  46. 46.
    Cohen J, Glauser MP. Septic shock: treatment. Lancet 1991;338:736–9.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • B. C. M. J. Takx-Köhlen
    • 1
  1. 1.Department of Clinical Pharmacy and ToxicologyUniversity Hospital of MaastrichtAZ Maastrichtthe Netherlands

Personalised recommendations